Live Breaking News & Updates on Co Founder Eric Schuur
Stay updated with breaking news from Co founder eric schuur. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HepaTx appoints Salah Kivlighn as new CEO News provided by Share this article Share this article PALO ALTO, Calif., April 15, 2021 /PRNewswire/ HepaTx Corporation, a preclinical stage company developing cell therapies for the treatment of liver disease, is pleased to announce the appointment of Salah Kivlighn, PhD as Chief Executive Office. An experienced business leader, Dr. Kivlighn will succeed Co-founder Eric Schuur, PhD and assume responsibilities on April 15 th, 2021. Dr. Kivlighn brings a rare blend of science and business acumen to HepaTx. His experience spans therapeutic classes including oncology, vaccines, immuno-oncology, and cardiovascular disease treatments and multiple aspects of drug development and commercialization. His accomplishments include: guided the discovery, evolution, and commercialization of Losartan (Cozaar®), a market-leading antihypertensive drug becoming a $3.5B franchise (Merck & Co.); co-led the development and commerc ....